<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/CC8F6421-0BC9-43BF-BBE0-BBABE6DE25E5"><gtr:id>CC8F6421-0BC9-43BF-BBE0-BBABE6DE25E5</gtr:id><gtr:name>Ai2 Limited</gtr:name><gtr:address><gtr:line1>THE MANCHESTER INCUBATOR , BUILDING GRAFTON STREET</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CC8F6421-0BC9-43BF-BBE0-BBABE6DE25E5" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>CC8F6421-0BC9-43BF-BBE0-BBABE6DE25E5</gtr:id><gtr:name>Ai2 Limited</gtr:name><gtr:address><gtr:line1>THE MANCHESTER INCUBATOR , BUILDING GRAFTON STREET</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100000.0</gtr:offerGrant><gtr:projectCost>184899.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710124"><gtr:id>C5C809E1-9EAB-4DE6-8A4B-A85ECB62158F</gtr:id><gtr:title>Re-engineering an innovative opthalmic anti-infective technology for use in oral care.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710124</gtr:grantReference><gtr:abstractText>Ai2 is a UK-based biotechnology company specializing in anti-infective peptide technology
derived from the human protein Apolipoprotein E that combines potent efficacy with an
excellent safety profile. This technology has been developed for application to contact lenses
and lens care products with a license deal signed with Sauflon Pharmaceuticals to apply the
technology to their products. Ai2 is now looking at re-engineering this technology for other
applications with a high antimicrobial need and have identified oral care as a market that
would benefit from this technology.
Various oral microbes are associated with the formation of dental caries and gingivitis that
result in poor dental health and may cause tooth loss. A good dental hygiene routine using
oral care products, some of which make use of added antimicrobial agents, can reduce the risk
of dental disease but these agents each have significant problems associated with their use
including difficulties with formulation into products, safety concerns as well as concerns
regarding their effect on the environment. A more effective agent is needed as despite
widespread use of current technology dental disease is still a major worldwide problem.
Ai2 believes that its anti-infective peptide technology has the potential to address all of the
problems that current technology in oral care has but the feasibility of application of this
technology to oral care products needs to be addressed. This project seeks to establish the
feasibility of re-engineering Ai2?s technology to oral care applications and will examine the
efficacy of a library of peptides against relevant organisms, their compatibility with both
human tissue and oral care product ingredients and test lead peptide activity in a dental
biofilm model. At the end of this project Ai2 will have a data portfolio demonstrating the
feasibility of application of our peptide technology to oral care products with which to
approach potential licensees.</gtr:abstractText><gtr:fund><gtr:end>2013-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710124</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>